• Capecitabine in Patient-Derived Assembloids

  2026-08-23

  Capecitabine gives researchers a practical way to compare fluoropyrimidine response in tumor organoids versus matched tumor–stroma assembloids. This workflow connects enzymatic prodrug activation, apoptosis readouts, and microenvironment-driven resistance for more informative preclinical oncology research.

• Cefepime (BMY-28142) Research Workflows

  2026-08-22

  Build resistance-aware bacterial infection models with Cefepime (BMY-28142), linking β-lactam activity to pathogen genotype, plasmid transfer, and CNS-relevant exposure questions. This workflow emphasizes fresh solution handling, matched controls, and neurotoxicity-aware interpretation rather than relying on a single susceptibility endpoint.

• Plerixafor: A CXCR4 Probe for Tumor Trafficking

  2026-08-22

  Plerixafor (AMD3100) is more than a CXCR4 antagonist for cell migration studies: it can help separate chemokine-guided platelet entry into tumors from platelet effector functions. This article translates the CXCL12/CXCR4 findings into practical assay-design, interpretation, and translational research strategies.

• BH3 Mimetics in TP53-Wild-Type Breast Cancer

  2026-08-21

  The reference study shows that chemotherapy-induced senescent breast cancer cells can remain biologically dangerous and may be selectively eliminated with BH3 mimetics. Its combination of cell-state profiling, apoptosis assays, gene editing, and sequential treatment in mice provides a framework for targeting residual disease in TP53-wild-type tumors.

• Coumestrol: From ER Antagonism to Ferroptosis

  2026-08-20

  Coumestrol is a phytoestrogen estrogen receptor antagonist with nanomolar ERα and ERβ activity and broader nuclear-receptor effects. This article presents an exposure-aware framework connecting receptor pharmacology with PMAIP1-dependent ferroptosis in rheumatoid arthritis fibroblast models.

• FXR Phase Separation Clusters Coronavirus DMVs

  2026-08-20

  Li et al. identify fragile X–related proteins as host organizers that cluster β-coronavirus double-membrane vesicles through liquid–liquid phase separation. The study links condensate biology to replication-organelle architecture and SARS-CoV-2 replication, while suggesting imaging and perturbation strategies for investigating host–virus membrane remodeling.

• Calpain Inhibitor II, ALLM in Protease Research

  2026-08-19

  Calpain Inhibitor II, also called ALLM, is a cell-permeable peptide inhibitor with activity against calpain I, calpain II, cathepsin L, and cathepsin B. Its reported effects in human leukemia and lymphoma models support use as a mechanistic apoptosis and protease inhibition tool, but its multi-protease profile limits interpretation as a selective calpain-2 probe.

• Cefepime (BMY-28142) Assay Guide

  2026-08-19

  A scenario-driven guide to using Cefepime (BMY-28142), SKU BA1013, in bacterial infection models and cell-based viability workflows. It connects formulation and handling decisions with resistance interpretation, neurotoxicity precautions, and practical vendor-selection criteria.

• Dasatinib Monohydrate in Tumor Assembloids

  2026-08-18

  Dasatinib Monohydrate (BMS-354825) provides a mechanistically defined kinase-perturbation arm for patient-derived gastric cancer assembloids, complementing its established role in leukemia research. This workflow helps distinguish tumor-cell sensitivity from stromal protection while preserving matched, patient-specific biology.

• MK-4827: Reframing PARP Inhibition for Translation

  2026-08-18

  MK-4827, also known as Niraparib, offers a high-potency platform for studying PARP-1/-2 inhibition, synthetic lethality, and combination strategies in DNA damage response research. Emerging evidence that hyperthermia can reduce BRCA2 protein and sensitize BRCA2-proficient ovarian cancer broadens the translational framework beyond mutation-defined tumors.

• Crizotinib hydrochloride in Gastric Cancer Assays

  2026-08-17

  Learn how to use Crizotinib hydrochloride as a mechanism-focused ALK kinase inhibitor in matched gastric tumor organoids and stromal assembloids. This workflow separates direct kinase response from microenvironment-driven resistance by combining viability, phosphorylation, imaging, and transcriptomic readouts.

• RRP Restores Lipid Metabolism in Hepatic IRI

  2026-08-17

  The reference study shows that Radix Rehmanniae Praeparata extracts alleviate hepatic ischemia-reperfusion injury by correcting cholesterol synthesis and efflux in mice and lipid-loaded hepatocytes. Its key mechanistic contribution is linking AMPK activation and mTOR inhibition to suppression of SCAP–SREBP2 processing, enhanced INSIG1 and ERLIN1 activity, and LXRα-dependent cholesterol efflux.

• Hexamethonium Bromide in Autonomic Research

  2026-08-16

  Learn how to use Hexamethonium Bromide to separate ganglionic contributions from vascular and cardiac mechanisms in neuronal signaling and hypertension models. A practical workflow connects fresh-solution handling, telemetry, sex-aware study design, and troubleshooting to findings from conscious-mouse research.

• Cy3 Goat Anti-Human IgG (H+L) Antibody Guide

  2026-08-15

  This scenario-based guide explains how Cy3 Goat Anti-Human IgG (H+L) Antibody, SKU K1208, can support orthogonal immunodetection in cell viability, proliferation, and cytotoxicity workflows. It covers assay compatibility, fluorescence controls, protocol optimization, interpretation, and practical reagent-selection criteria.

• Bleomycin Sulfate: Mechanism, Evidence, and Workflow

  2026-08-14

  Bleomycin Sulfate is a DNA strand break inducer used in oncology, cellular injury, and pulmonary fibrosis research. Its cell-type-dependent cytotoxicity and oxygen-dependent DNA damage require solvent, storage, exposure, and endpoint controls.

7900 records 1/527 page Next 12345 下5页 Last page